Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 269
- Registration Number
- NCT02589639
- Locations
- 🇯🇵
Nishinomiya Municipal Central Hospital, Hyogo, Nishinomiya, Japan
🇯🇵North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun, Japan
🇯🇵Chiyoda Houjin Clinic, Tokyo, Chiyoda-ku, Japan
Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2015-10-28
- Last Posted Date
- 2019-01-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 65
- Registration Number
- NCT02589626
- Locations
- 🇯🇵
Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama, Japan
🇯🇵Kubota Clinic, Kanagawa, Kawasaki, Japan
🇯🇵Kunisaki Makoto Clinic, Fukuoka, Fukuoka, Japan
Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 977
- Registration Number
- NCT02580591
- Locations
- 🇺🇸
International Research Associates, LLC, Hialeah, Florida, United States
🇺🇸University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Sestron Clinical Research, Marietta, Georgia, United States
Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 105
- Registration Number
- NCT02579603
- Locations
- 🇺🇸
Western CT Medical Group, P.C., Danbury, Connecticut, United States
🇫🇷HOP Avicenne, Bobigny, France
🇫🇷HOP de la Cavale Blanche, Brest, France
Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02577315
- Locations
- 🇷🇺
1276.27.001 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation
DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)
- First Posted Date
- 2015-10-14
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02574845
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
Relative Bioavailability of 2 Oral Formulations of Nintedanib
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 70
- Registration Number
- NCT02572752
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach, Germany
Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2015-12-31
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT02572609
Actual Use Study of Tamsulosin in Men
- First Posted Date
- 2015-10-09
- Last Posted Date
- 2020-04-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1117
- Registration Number
- NCT02573311
- Locations
- 🇺🇸
Kroger Pharmacy #342, Cary, North Carolina, United States
🇺🇸Garden Drug, Fort Lauderdale, Florida, United States
🇺🇸Eagle Pharmacy, Houston, Texas, United States
Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers
- Conditions
- Healthy
- Interventions
- Drug: BI 655130 (spesolimab)Drug: Placebo
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT02525679
- Locations
- 🇧🇪
SGS Life Science Services - Clinical Research, Antwerpen, Belgium